We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+43%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$926M
AUM Growth
+$212M
Cap. Flow
-$7.45M
Cap. Flow %
-0.8%
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
24
Reduced
46
Closed
5

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$17.6M
2
BAX icon
Baxter International
BAX
+$8.28M
3
XLRN
Acceleron Pharma
XLRN
+$8.19M
4
UNH icon
UnitedHealth
UNH
+$7.16M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.7M
2
ESPR
Esperion Therapeutics
ESPR
+$7.02M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$6.08M
4
NKTR icon
Nektar Therapeutics
NKTR
+$5.93M
5
MGNX icon
MacroGenics
MGNX
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 94.86%
2 Communication Services 1.03%
3 Energy 0.07%
4 Technology 0.06%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
26
DELISTED
Acceleron Pharma
XLRN
$14.8M 1.6%
155,000
+85,000
+121% +$8.19M
CVS icon
27
CVS Health
CVS
$121B
$14.7M 1.59%
227,000
-33,000
-13% -$2.08M
BSX icon
28
Boston Scientific
BSX
$73.3B
$14.4M 1.56%
410,000
-155,000
-27% -$5.58M
ARNA
29
DELISTED
Arena Pharmaceuticals Inc
ARNA
$13.3M 1.43%
210,778
-29,222
-12% -$1.61M
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
$12.7M 1.38%
75,000
-10,000
-12% -$1.49M
MRK icon
31
Merck
MRK
$322B
$12.4M 1.34%
167,680
-5,240
-3% -$394K
ITCI
32
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.2M 1.32%
475,000
-92,534
-16% -$1.87M
MDT icon
33
Medtronic
MDT
$114B
$12M 1.3%
130,780
– –
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.4M 1.23%
100,000
-30,000
-23% -$2.91M
COO icon
35
Cooper Companies
COO
$14.8B
$11.3M 1.23%
160,000
+64,000
+67% +$4.74M
LIVN icon
36
LivaNova
LIVN
$4.2B
$10.6M 1.14%
220,000
+30,000
+16% +$1.5M
ADVM
37
DELISTED
Adverum Biotechnologies
ADVM
$10.4M 1.13%
50,000
-5,000
-9% -$886K
ISRG icon
38
Intuitive Surgical
ISRG
$137B
$9.69M 1.05%
51,000
-18,000
-26% -$3.23M
LVGO
39
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$9.4M 1.02%
+125,000
New +$6.54M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$2.98B
$9.33M 1.01%
340,000
-25,000
-7% -$822K
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$29.2B
$9.2M 0.99%
62,095
-17,905
-22% -$2.41M
NBIX icon
42
Neurocrine Biosciences
NBIX
$16.7B
$9.15M 0.99%
75,000
-55,000
-42% -$6.08M
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$8.71M 0.94%
590,000
-130,000
-18% -$1.92M
XNCR icon
44
Xencor
XNCR
$1.57B
$8.42M 0.91%
260,000
-40,325
-13% -$1.24M
EW icon
45
Edwards Lifesciences
EW
$53.1B
$8.29M 0.9%
120,000
-51,000
-30% -$3.62M
DVAX
46
DELISTED
Dynavax Technologies
DVAX
$8.21M 0.89%
925,534
-74,466
-7% -$376K
BAX icon
47
Baxter International
BAX
$14.4B
$8.18M 0.88%
+95,000
New +$8.28M
REGN icon
48
Regeneron Pharmaceuticals
REGN
$82.5B
$7.8M 0.84%
+12,500
New +$7.1M
HCA icon
49
HCA Healthcare
HCA
$89.2B
$7.28M 0.79%
75,000
-15,000
-17% -$1.56M
EXAS
50
DELISTED
Exact Sciences
EXAS
$6.96M 0.75%
80,000
-24,300
-23% -$1.94M
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rhenman & Partners Asset Management held 99 positions worth $926M, up 30% from $714M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q2 2020 filing shows 14 new, 24 increased, 46 reduced and 5 closed positions. Its largest new stake was Gilead Sciences: 230,000 shares worth $17.7M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Communication Services and Energy.

  • Rhenman & Partners Asset Management's largest Q2 2020 buy was Gilead Sciences: 230,000 shares worth $17.7M.
  • Rhenman & Partners Asset Management added most to Acceleron Pharma in Q2 2020, an estimated $8.19M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $10.7M.
  • Rhenman & Partners Asset Management fully exited Stemline Therapeutics, Inc. in Q2 2020, selling an estimated $3.15M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $926M portfolio in Q2 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $926M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2020, filed 16 Jul 2020.